Scholarlink

Background <p>With the advent of novel therapeutic agents addressing the need for more effective and personalized treatment options, the management of mantle cell lymphoma (MCL) has rapidly evolved. Advances such as targeted and immunotherapies hold promise for improving survival and overcoming treatment resistance.</p> Objective <p>This manuscript reviews recent clinical trial data and real-world analyses on MCL treatment, highlighting the shift away from autologous stem cell transplantation (ASCT) and the emerging role of targeted agents and immunotherapies.</p> Materials and methods <p>We analyzed results from key clinical trials, including the TRIANGLE, ECOG-ACRIN 4151, ENRICH, and SHINE studies, as well as real-world data. Emphasis was placed on treatment outcomes, progression-free survival (PFS), overall survival (OS), and treatment-related toxicities.</p> Results and conclusion <p>The integration of BTK inhibitors, reduced reliance on ASCT, and robust maintenance strategies have transformed first-line MCL treatment paradigms. In relapsed/refractory settings, various generations of BTK inhibitors and immunotherapies hold great promise for sustained disease control, improved long-term survival, and enhanced quality of life, offering novel modes of action that can overcome resistance mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stellenwert neuer Therapiemodalitäten beim Mantelzelllymphom

  • 期刊论文

  • 发表日期：

    2025年4月7日

查看全文
  • Ron D. Jachimowicz,
  • Martin Dreyling

摘要

Background

With the advent of novel therapeutic agents addressing the need for more effective and personalized treatment options, the management of mantle cell lymphoma (MCL) has rapidly evolved. Advances such as targeted and immunotherapies hold promise for improving survival and overcoming treatment resistance.

Objective

This manuscript reviews recent clinical trial data and real-world analyses on MCL treatment, highlighting the shift away from autologous stem cell transplantation (ASCT) and the emerging role of targeted agents and immunotherapies.

Materials and methods

We analyzed results from key clinical trials, including the TRIANGLE, ECOG-ACRIN 4151, ENRICH, and SHINE studies, as well as real-world data. Emphasis was placed on treatment outcomes, progression-free survival (PFS), overall survival (OS), and treatment-related toxicities.

Results and conclusion

The integration of BTK inhibitors, reduced reliance on ASCT, and robust maintenance strategies have transformed first-line MCL treatment paradigms. In relapsed/refractory settings, various generations of BTK inhibitors and immunotherapies hold great promise for sustained disease control, improved long-term survival, and enhanced quality of life, offering novel modes of action that can overcome resistance mechanisms.